ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Emergent advances agreement for J&J COVID-19 vaccine

by Rick Mullin
July 11, 2020 | APPEARED IN VOLUME 98, ISSUE 27

 

Emergent BioSolutions has signed a 5-year contract to provide large-scale manufacturing of Johnson & Johnson’s investigational COVID-19 vaccine, Ad26.COV2-S, at its facility in Baltimore. The deal is valued at $480 million for the first 2 years. It follows a $135 million agreement the firms announced in April to reserve capacity and transfer technology. J&J also has a deal to use capacity at Catalent’s biologic drug facility in Bloomington, Indiana. The drugmaker has said it plans to produce 1 billion doses of the adenovirus-based vaccine.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment